ADmit Therapeutics

ADmit Therapeutics, based in Barcelona, is a promising company in the Alzheimer's disease space, focusing on early detection technology. Unlike traditional methods that rely on later-stage diagnoses, ADmit Therapeutics aims to identify the disease earlier, enabling timely interventions to slow disease progression and improve quality of life. Operating on a B2B model, the company partners with healthcare providers and pharmaceutical firms, expanding its market reach. Backed by investors like WA4STEAM, EIC Accelerator, and Ship2B, ADmit Therapeutics enjoys financial stability and validation of its innovative approach. In a market where delayed diagnosis accelerates disease progression, their focus on early detection sets them apart and meets the growing demand for preemptive healthcare solutions.